ATACAND

DRUG4 trials

Sponsors

AstraZeneca, Mayo Clinic, GlaxoSmithKline, Baylor Research Institute

Conditions

Cardiovascular DiseaseChronic Kidney DiseaseHypertensionMitral RegurgitationType 2 Diabetes

Phase 1

Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions

CompletedNCT02254447

GlaxoSmithKlineCardiovascular Disease

Start: 2014-12-02End: 2015-01-08Updated: 2018-03-12

Phase 3

TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial

CompletedNCT00227318

AstraZenecaHypertension

Start: 1998-07-31End: 2005-10-31Target: 1000Updated: 2011-08-30

Phase 4

Angiotensin-II Blockade in Mitral Regurgitation

CompletedNCT00587470

Mayo ClinicMitral Regurgitation

Start: 1998-08-31End: 2001-08-31Updated: 2010-10-15

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Not yet recruitingNCT07547878

Baylor Research InstituteChronic Kidney Disease, Type 2 Diabetes

Start: 2026-04-30End: 2029-03-31Target: 64Updated: 2026-05-08

Related Papers

Feasibility of treating prehypertension with an angiotensin-receptor blocker.

2006-03-14617 citations